Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Packungsgröße | SKU | Verfügbarkeit | Preis |
|---|---|---|---|
| 5 mg | Warenkorb auf Verfügbarkeit prüfen | € 102,00 € 86,70 | |
| 25 mg | Warenkorb auf Verfügbarkeit prüfen | € 398,00 |
Über diesen Artikel
Empirische Formel (Hill-System):
C19H25NOS·HCl
CAS-Nummer:
Molekulargewicht:
351.93
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
€ 86,70
Listenpreis€ 102,00Sparen Sie 15%Aktion nur im Web
Warenkorb auf Verfügbarkeit prüfen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Level
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
solubility
DMSO: >10 mg/mL
originator
UCB Inc.
storage temp.
room temp
SMILES string
Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2
InChI
1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1
InChI key
CEXBONHIOKGWNU-NTISSMGPSA-N
Biochem/physiol Actions
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.
Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.
Features and Benefits
This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| assay ≥98% (HPLC) | assay - | assay - | assay ≥98% (HPLC) |
| form solid | form - | form - | form powder |
| Quality Level 100 | Quality Level - | Quality Level - | Quality Level 100 |
| storage temp. room temp | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. room temp |
| solubility DMSO: >10 mg/mL | solubility - | solubility - | solubility DMSO: >10 mg/mL |
| storage condition desiccated | storage condition - | storage condition - | storage condition desiccated |
Still not finding the right product?
Explore all of our products under Rotigotin -hydrochlorid
Lagerklasse
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Lawrence W Elmer et al.
Parkinsonism & related disorders, 18(5), 488-493 (2012-02-14)
This prospective, open-label extension (SP702; NCT00594165) of a 6-month double-blind, randomized study investigated the long-term safety and tolerability of rotigotine transdermal system in early Parkinson's disease (PD). Patients with early-stage idiopathic PD received transdermal rotigotine for up to 6 years
Nikos Gorgoraptis et al.
Brain : a journal of neurology, 135(Pt 8), 2478-2491 (2012-07-05)
Hemispatial neglect following right-hemisphere stroke is a common and disabling disorder, for which there is currently no effective pharmacological treatment. Dopamine agonists have been shown to play a role in selective attention and working memory, two core cognitive components of
S R Schreglmann et al.
Parkinsonism & related disorders, 18(2), 207-209 (2011-10-28)
Dopaminergic drugs are the mainstay of treatment for restless legs syndrome (RLS). We analyzed the frequency and clinical characteristics of impulse control disorders (ICD) in patients with RLS on transdermal rotigotine treatment. Retrospective case series at a university movement disorder
Global Trade Item Number
| SKU | GTIN |
|---|---|
| R9281-25MG | 04061836824143 |
| R9281-5MG | 04061833026663 |


